deferiprone has been researched along with Adult Neuroaxonal Dystrophy in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In one case, we managed to stabilize disease progression for more than 11 years." | 1.72 | Conservative Iron Chelation for Neuroferritinopathy. ( Defebvre, L; Devos, D; Huin, V; Kuchcinski, G; Marchand, F; Moreau, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marchand, F | 1 |
| Moreau, C | 1 |
| Kuchcinski, G | 1 |
| Huin, V | 1 |
| Defebvre, L | 1 |
| Devos, D | 1 |
| Cossu, G | 1 |
| Abbruzzese, G | 1 |
| Matta, G | 1 |
| Murgia, D | 1 |
| Melis, M | 1 |
| Ricchi, V | 1 |
| Galanello, R | 1 |
| Barella, S | 1 |
| Origa, R | 1 |
| Balocco, M | 1 |
| Pelosin, E | 1 |
| Marchese, R | 1 |
| Ruffinengo, U | 1 |
| Forni, GL | 1 |
| Garringer, HJ | 1 |
| Irimia, JM | 1 |
| Li, W | 1 |
| Goodwin, CB | 1 |
| Richine, B | 1 |
| Acton, A | 1 |
| Chan, RJ | 1 |
| Peacock, M | 1 |
| Muhoberac, BB | 1 |
| Ghetti, B | 1 |
| Vidal, R | 1 |
| Storti, E | 1 |
| Cortese, F | 1 |
| Di Fabio, R | 1 |
| Fiorillo, C | 1 |
| Pierallini, A | 1 |
| Tessa, A | 1 |
| Valleriani, A | 1 |
| Pierelli, F | 1 |
| Santorelli, FM | 1 |
| Casali, C | 1 |
4 other studies available for deferiprone and Adult Neuroaxonal Dystrophy
| Article | Year |
|---|---|
Conservative Iron Chelation for Neuroferritinopathy.
Topics: Deferiprone; Disease Progression; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Neuroaxo | 2022 |
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.
Topics: Adult; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Longitudinal S | 2014 |
Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary Ferritinopathy.
Topics: Animals; Apoferritins; Cell Survival; Cells, Cultured; Chelation Therapy; Deferiprone; Disease Model | 2016 |
De novo FTL mutation: a clinical, neuroimaging, and molecular study.
Topics: Adult; Brain; Cholinergic Antagonists; Deferiprone; Dopamine Agonists; Humans; Iron Metabolism Disor | 2013 |